Phase 1 (Weeks 1 to 2): 0.25 mg subcutaneous injection once daily, morning on empty stomach Phase 2 (Weeks 3 to 6): Maintain 0.25 mg or increase to 0.5 mg based on response and tolerance Phase 3 (Weeks 7 to 8): Continue or begin taper depending on symptom improvement Maintenance: Consider cycling 4 weeks on, 2 weeks off for long-term management Oral dosing requires higher amounts to compensate for bioavailability differences
Typically, this irritation leads to an inflammatory response, but administering BPC-157 beforehand seemed to lessen that response in a dose-dependent manner [6]
This is because extreme temperatures and pressure can affect the glass of the vial as well as the plastic stopper
Xu X, Wu J, Liu Y, Saw PE, Tao W, Yu M, Zope H, Si M, Victorious A, Rasmussen J, et al
$16,487 and 8.5% vs